التفاصيل البيبلوغرافية
| العنوان: |
ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy |
| المؤلفون: |
Westin, Jason, Burke, John, Lynch, Ryan, Abramson, Jeremy, Stevens, Don, Matasar, Matthew, Fitzgerald, Lindsey, Zausner Skarbnik, Alan, Iragavarapu, Chaitanya, Essell, James, Hunter, Bradley, Merchant, Akil, Varadarajan, Indumathy, Tandra, Anand, Licitra, Edward, Bryan, Locke, Patel, Rushang D., Behl, Rajesh, Sharmann, Jeff, Holmes, Houston E., Fanning, Suzanne, Yimer, Habte, Gandhi, Mitul, Simmons, Gary, Feng, Amy, Navale, Lynn, Ghatta, Srinivas, Le Gall, John B., Herrera, Alex F. |
| المصدر: |
In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S251-S251 |
| قاعدة البيانات: |
ScienceDirect |
Full Text via ClinicalKey 
Full Text Finder